BioSpace News Archive

Immuneering Corporation announced that it will hold a virtual Investor Event concurrent with a data presentation on its universal-RAS program IMM-1-104 at the American Association for Cancer Research Annual Meeting 2023.

Immunexpress, Pty Ltd. announced today a poster presentation at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) which evaluates the use of SeptiCyte® RAPID as a tool to determine sepsis status in patients admitted to the Intensive Care Unit (ICU).

BIOREM Inc. (TSXV: BRM) (“Biorem” or “the Company”) today announced its results for the three and twelve-month periods ended December 31, 2022.

ClexBio, an innovative regenerative medicine company focused on developing next-generation bioengineered implants, is proud to announce the appointment of Professor David Weitz to its Scientific Advisory Board.

Senseonics Holdings, Inc. announced that it had made equity grants to new employees under its 2019 Inducement Plan in accordance with NYSE American Company Guide Section 711.

Funds managed by Farallon Capital Management L.L.C. own approximately 7.2% of the outstanding shares of Exelixis, Inc., making it the Company’s largest active shareholder.

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced receipt of a written response from the U.S. Food and Drug Administration (FDA) on the request for a Type B pre-IND (Investigational New Drug) meeting on the planned pre-clinical development of NM-136 for the treatment of obesity.

CytoDyn Inc. announced that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Hansen, our newly appointed Head of Research and Basic Science, will host an investment community webcast to provide a Company update on Tuesday, April 11, 2023.

Deka Biosciences (“Deka”), a clinical-stage biotechnology company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced today that the first subject has been dosed in a Phase 1 clinical trial of DK210 (EGFR) at NEXT Oncology in Fairfax, Virginia.

Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK’s Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announced a collaboration to deploy NeXT Personal, a personalized liquid biopsy-based research assay, for the TRACERx study, a groundbreaking lung cancer initiative funded by Cancer Research UK.